CreatorsPublishersAdvertisers
View more in
Cancer

Tislelizumab Plus Chemotherapy Elicits PFS Benefit in Advanced Squamous NSCLC

onclive.com
 2021-09-08

Tislelizumab plus chemotherapy demonstrated clinically meaningful improvements in progression-free survival vs standard of care chemotherapy as a first-line treatment for patients with stage IIIB and those with stage IV advanced squamous non–small cell lung cancer. Tislelizumab plus chemotherapy demonstrated clinically meaningful improvements in progression-free survival (PFS) vs standard of...

www.onclive.com

Comments / 0

Comments / 0